Global Bipolar Disorder Therapeutics Market (By Drug Class and Mechanism of Action) – Prospective Landscape, Size, Share, Growth, Opportunities and Industry Forecast 2018 – 2025

Published DateReport CodeNo. of PagesReport Format
Sept – 2019AMR-9003110PDF / Excel

SelectLicense Type

The global bipolar disorder therapeutics market is dominated by the antipsychotic drug segment

The global market for bipolar disorder therapeutic market is fueled by increasing prevalence of manic depression, social programs to spread awareness of the effects of bipolar disorders, high demand for antidepressant drugs, and the need to ease the burden of bipolar disorder disease. Nevertheless, it is expected that the shortage of proper tests and treatments for disorder detection and the side effects affiliated with bipolar disorder treatment will hinder market growth. On the other hand, drug combination therapy advancements provide growth opportunities in the near future.

Technological progress further helps the growth of the industry as the use of smart watches, smartphones, and wearable devices enables the accurate detection of the state of mind and mental condition of a patient and also successfully captures behavioral, physiological, and environmental data. In addition to the advent of digital mental disorder body-management tools, timely involvement and better observance to prescribed treatment is feasible.

The global bipolar disorder market is classified on the basis of mechanism of action, drugs class, and geography. On the basis of mechanism of action, it is segmented into serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, beta blockers and benzodiazepines. Based on drug class, it is fragmented into antipsychotics drugs, mood stabilizers, anticonvulsants, antianxiety drugs and antidepressant drugs. Geography wise, it is analyzed across North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

The market is dominated by the antipsychotic drug segment. It is used as part of a combination therapy with SSRI and has shown positive results, causing more doctors to choose these medicines. Anticonvulsants serve as an appropriate mood stabilizer for mental illness by mitigating bipolar disorder symptoms of depression without exacerbating mania. These medications overcome the constraints of traditional antidepressant drugs as they normalize the mood without triggering acceleration or mania. The intensive use of anticonvulsants, either as a particular drug or as part of hybrid therapies, will drive segment growth rapidly over the forecast period.

As a result of increased consciousness among people, new product innovation of bipolar disease and increased incidence of bipolar disorders, North America continues to dominate the global bipolar disorder therapy market. In the United States, 48 % of people with schizophrenia are undergoing treatment, as per the National Institutes of Health. Europe is the second largest market for bipolar disorder therapeutics. The Asia Pacific market is expected to increase at a faster growth rate as a result of growing awareness among people, increased investment in R&D, utilization of skilled labor to manufacture products and increased investment by pharmaceutical industry. According to Graphiq, Inc., since 1990, an average of 0.6 percent per year, 100 thousand individual lost their lives as a result of bipolar disorder in India which has increased by 14 to 15 percent.

The key global players of bipolar disorder therapeutics market are Pfizer Inc., Glaxo SmithKline (GSK), Eli Lilly, Janssen Pharmaceuticals, Novartis AG, Allergan Plc., Otsuka Holdings Co. Ltd, AbbVie Inc., Bristol-Myers Squibb Company and AstraZeneca.

Bipolar disorder, also recognized as severe depression, is a mental illness that may lead to an increase in depressive moments and high emotional state. Psychotherapy and treatments such as antipsychotics and mood stabilizers are included in the medication of bipolar disorder. Growth in the bipolar disorder therapeutic industry is expected to speed up significantly over the next few years, driven by the increased prevalence of mental health disorders (MHDs) worldwide.

Most MHDs co-exist with other diseases like diabetes, cardiovascular disease and obesity, according to the CDC. Depression affected nearly 10%-12% of the younger population in the U.S. in 2017, and 3%-4% of the population ended up living with serious mental illnesses such as bipolar disorder, schizophrenia and major depression. The growing incidence of these MHDs leads to a great need to develop the most appropriate bipolar disorder treatment.

Bipolar disorder affects more than 5 million people in the United States, according to Pfizer, Inc. Bipolar episodes are distinguished by a dramatic behavioral change and emotional state, ranging from exaggerated and happy to terribly sad and depressive state. These abnormalities have various types of episodes, such as hypomanic episodes, manic episodes, mixed episodes and episodes of depression. Bipolar disorder triggers include stressful events in life, childhood trauma, genetic inheritance and problems with self-esteem.

Throughout the world, people represented “March 30” as a World Bipolar Day to create awareness of the disorder and eliminate the mental disorder stigma. Huge number of people with this mental condition depend on alcohol to lift their emotional state. Around 27% of people with bipolar disorder become dependent on alcohol, while over 15% are engaged in abuse of alcohol, as per the National Institute on Alcohol Abuse and Alcoholism.

Rising bipolar disorder prevalence, technological advancement, high unmet medical needs, and government initiatives are major factors that accelerate the growth of the bipolar disorder therapeutic market. The Salk Institute for Biological Studies and Johns Hopkins University School of Medicine co-led a $15.4 million commitment in 2016, as per the National Institute of Mental Health, to design new systems to quickly monitor drug databases for potential efficiency against bipolar disorder and schizophrenia. The other factors probable to fuel the bipolar disorder therapeutic market are excessive investment in research and development and cooperative activities between corporations for product innovation. Corium and Aequus started partnership on product design in 2015 focusing on CNS illnesses such as schizophrenia, bipolar disorder, autistic disorder, and other major depressive diseases. Stringent regulations, however, act as a major constraint on the bipolar disorder therapeutic market.

With the emergence of several vendors offering products for bipolar disorder treatment, the global bipolar disorder therapy market is expected to experience strong competition and diminishing profitability. Most sellers focus on entering into strategic partnerships to develop the most efficient bipolar treatment therapy and expand their portfolio of products. Many international and national vendors remain competitive for their share of the global bipolar disorder therapeutic market, and players need to distinguish to gain essential traction over their counterparts.

The key global players of bipolar disorder therapeutics market are Pfizer Inc., Glaxo SmithKline (GSK), Eli Lilly, Janssen Pharmaceuticals, Novartis AG, Allergan Plc., Otsuka Holdings Co. Ltd, AbbVie Inc., Bristol-Myers Squibb Company and AstraZeneca.

Chapter 1. Executive Summary

Chapter 2. Market Introduction

Chapter 3. Global Bipolar Disorder Therapeutics Market – Analysis and Revenue Forecast 2018-2025 – Key Industry Dynamics

  • 3.1. Key Market Drivers
  • 3.2. Key Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Future Trends
  • 3.5. Impact Analysis of Drivers and Restraints

Chapter 4. Global Bipolar Disorder Therapeutics Market – Analysis and Revenue Forecast 2018-2025

Chapter 5. Global Bipolar Disorder Therapeutics Market – Analysis and Revenue Forecast 2018-2025 – By Drug Class

  • 5.1. Mood Stabilizers
  • 5.2. Anticonvulsants
  • 5.3. Antipsychotic Drugs
  • 5.4. Antidepressant Drugs
  • 5.5. Antianxiety Drugs

Chapter 6. Global Bipolar Disorder Therapeutics Market – Analysis and Revenue Forecast 2018-2025 – Mechanism of Action

  • 6.1. Selective Serotonin Reuptake Inhibitor
  • 6.2. Serotonin Norepinephrine Reuptake Inhibitors
  • 6.3. Tricyclic Antidepressants
  • 6.4. Monoamine Oxidase Inhibitors
  • 6.5. Benzodiazepines
  • 6.6. Beta Blockers

Chapter 7. Global Bipolar Disorder Therapeutics Market – Analysis and Revenue Forecast 2018-2025 – By Region

  • 7.1. North America
  • 7.2. Europe
  • 7.3. Asia-Pacific
  • 7.4. Latin America
  • 7.5. Middle East & Africa

Chapter 8. North America Bipolar Disorder Therapeutics Market – Analysis and Revenue Forecast 2018-2025

  • 8.1. North America Bipolar Disorder Therapeutics Market – By Drug Class
    • 8.1.1.Mood Stabilizers
    • 8.1.2.Anticonvulsants
    • 8.1.3.Antipsychotic Drugs
    • 8.1.4.Antidepressant Drugs
    • 8.1.5.Antianxiety Drugs
  • 8.2. North America Bipolar Disorder Therapeutics Market – By Mechanism of Action
    • 8.2.1.Selective Serotonin Reuptake Inhibitor
    • 8.2.2.Serotonin Norepinephrine Reuptake Inhibitors
    • 8.2.3.Tricyclic Antidepressants
    • 8.2.4.Monoamine Oxidase Inhibitors
    • 8.2.5.Benzodiazepines
    • 8.2.6.Beta Blockers
  • 8.3. North America Bipolar Disorder Therapeutics Market – By Country
    • 8.3.1.U.S.
    • 8.3.2.Canada

Chapter 9. Europe Bipolar Disorder Therapeutics Market – Analysis and Revenue Forecast 2018-2025

  • 9.1. Europe Bipolar Disorder Therapeutics Market – By Drug Class
    • 9.1.1.Mood Stabilizers
    • 9.1.2.Anticonvulsants
    • 9.1.3.Antipsychotic Drugs
    • 9.1.4.Antidepressant Drugs
    • 9.1.5.Antianxiety Drugs
  • 9.2. Europe Bipolar Disorder Therapeutics Market – By Mechanism of Action
    • 9.2.1.Selective Serotonin Reuptake Inhibitor
    • 9.2.2.Serotonin Norepinephrine Reuptake Inhibitors
    • 9.2.3.Tricyclic Antidepressants
    • 9.2.4.Monoamine Oxidase Inhibitors
    • 9.2.5.Benzodiazepines
    • 9.2.6.Beta Blockers
  • 9.3. Europe Bipolar Disorder Therapeutics Market – By Country
    • 9.3.1.Germany
    • 9.3.2.France
    • 9.3.3.UK
    • 9.3.4.Spain
    • 9.3.5.Italy
    • 9.3.6.Rest of Europe

Chapter 10. Asia-Pacific Bipolar Disorder Therapeutics Market – Analysis and Revenue Forecast 2018-2025

  • 10.1. Asia Pacific Bipolar Disorder Therapeutics Market – By Drug Class
    • 10.1.1.Mood Stabilizers
    • 10.1.2.Anticonvulsants
    • 10.1.3.Antipsychotic Drugs
    • 10.1.4.Antidepressant Drugs
    • 10.1.5.Antianxiety Drugs
  • 10.2. Asia Pacific Bipolar Disorder Therapeutics Market – By Mechanism of Action
    • 10.2.1.Selective Serotonin Reuptake Inhibitor
    • 10.2.2.Serotonin Norepinephrine Reuptake Inhibitors
    • 10.2.3.Tricyclic Antidepressants
    • 10.2.4.Monoamine Oxidase Inhibitors
    • 10.2.5.Benzodiazepines
    • 10.2.6.Beta Blockers
  • 10.3. Asia-Pacific Bipolar Disorder Therapeutics Market – By Country
    • 10.3.1.China
    • 10.3.2.India
    • 10.3.3.Japan
    • 10.3.4.South Korea
    • 10.3.5.Rest of Asia-Pacific

Chapter 11. Latin America Bipolar Disorder Therapeutics Market – Analysis and Revenue Forecast 2018-2025

  • 11.1. Latin America Bipolar Disorder Therapeutics Market – By Drug Class
    • 11.1.1.Mood Stabilizers
    • 11.1.2.Anticonvulsants
    • 11.1.3.Antipsychotic Drugs
    • 11.1.4.Antidepressant Drugs
    • 11.1.5.Antianxiety Drugs
  • 11.2. Latin America Bipolar Disorder Therapeutics Market – By Mechanism of Action
    • 11.2.1.Selective Serotonin Reuptake Inhibitor
    • 11.2.2.Serotonin Norepinephrine Reuptake Inhibitors
    • 11.2.3.Tricyclic Antidepressants
    • 11.2.4.Monoamine Oxidase Inhibitors
    • 11.2.5.Benzodiazepines
    • 11.2.6.Beta Blockers
  • 11.3. Latin America Bipolar Disorder Therapeutics Market – By Country
    • 11.3.1.Brazil
    • 11.3.2.Mexico
    • 11.3.3.Rest of Latin America

Chapter 12. Middle East & Africa Bipolar Disorder Therapeutics Market – Analysis and Revenue Forecast 2018-2025

  • 12.1. Middle East & Africa Bipolar Disorder Therapeutics Market – By Drug Class
    • 12.1.1.Mood Stabilizers
    • 12.1.2.Anticonvulsants
    • 12.1.3.Antipsychotic Drugs
    • 12.1.4.Antidepressant Drugs
    • 12.1.5.Antianxiety Drugs
  • 12.2. Middle East & Africa Bipolar Disorder Therapeutics Market – By Mechanism of Action
    • 12.2.1.Selective Serotonin Reuptake Inhibitor
    • 12.2.2.Serotonin Norepinephrine Reuptake Inhibitors
    • 12.2.3.Tricyclic Antidepressants
    • 12.2.4.Monoamine Oxidase Inhibitors
    • 12.2.5.Benzodiazepines
    • 12.2.6.Beta Blockers
  • 12.3. Middle East & Africa Bipolar Disorder Therapeutics Market – By Country
    • 12.3.1.UAE
    • 12.3.2.Saudi Arabia
    • 12.3.3.Turkey
    • 12.3.4.Rest of Middle East & Africa

Chapter 13. Competitive Analysis

  • 13.1.1.Competition Dashboard
  • 13.1.2.Company Profiles
    • 13.1.2.1. Pfizer Inc.
    • 13.1.2.2. Glaxo SmithKline
    • 13.1.2.3. Novartis AG
    • 13.1.2.4. Eli Lilly
    • 13.1.2.5. Janssen Pharmaceuticals
    • 13.1.2.6. Allergan Plc.
    • 13.1.2.7. Otsuka Holdings Co. Ltd
    • 13.1.2.8. AbbVie Inc.
    • 13.1.2.9. Bristol-Myers Squibb Company
    • 13.1.2.10. AstraZeneca
Report Synopsis

The global bipolar disorder therapeutics market is dominated by the antipsychotic drug segment

The global market for bipolar disorder therapeutic market is fueled by increasing prevalence of manic depression, social programs to spread awareness of the effects of bipolar disorders, high demand for antidepressant drugs, and the need to ease the burden of bipolar disorder disease. Nevertheless, it is expected that the shortage of proper tests and treatments for disorder detection and the side effects affiliated with bipolar disorder treatment will hinder market growth. On the other hand, drug combination therapy advancements provide growth opportunities in the near future.

Technological progress further helps the growth of the industry as the use of smart watches, smartphones, and wearable devices enables the accurate detection of the state of mind and mental condition of a patient and also successfully captures behavioral, physiological, and environmental data. In addition to the advent of digital mental disorder body-management tools, timely involvement and better observance to prescribed treatment is feasible.

The global bipolar disorder market is classified on the basis of mechanism of action, drugs class, and geography. On the basis of mechanism of action, it is segmented into serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, beta blockers and benzodiazepines. Based on drug class, it is fragmented into antipsychotics drugs, mood stabilizers, anticonvulsants, antianxiety drugs and antidepressant drugs. Geography wise, it is analyzed across North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

The market is dominated by the antipsychotic drug segment. It is used as part of a combination therapy with SSRI and has shown positive results, causing more doctors to choose these medicines. Anticonvulsants serve as an appropriate mood stabilizer for mental illness by mitigating bipolar disorder symptoms of depression without exacerbating mania. These medications overcome the constraints of traditional antidepressant drugs as they normalize the mood without triggering acceleration or mania. The intensive use of anticonvulsants, either as a particular drug or as part of hybrid therapies, will drive segment growth rapidly over the forecast period.

As a result of increased consciousness among people, new product innovation of bipolar disease and increased incidence of bipolar disorders, North America continues to dominate the global bipolar disorder therapy market. In the United States, 48 % of people with schizophrenia are undergoing treatment, as per the National Institutes of Health. Europe is the second largest market for bipolar disorder therapeutics. The Asia Pacific market is expected to increase at a faster growth rate as a result of growing awareness among people, increased investment in R&D, utilization of skilled labor to manufacture products and increased investment by pharmaceutical industry. According to Graphiq, Inc., since 1990, an average of 0.6 percent per year, 100 thousand individual lost their lives as a result of bipolar disorder in India which has increased by 14 to 15 percent.

The key global players of bipolar disorder therapeutics market are Pfizer Inc., Glaxo SmithKline (GSK), Eli Lilly, Janssen Pharmaceuticals, Novartis AG, Allergan Plc., Otsuka Holdings Co. Ltd, AbbVie Inc., Bristol-Myers Squibb Company and AstraZeneca.

Report Description

Bipolar disorder, also recognized as severe depression, is a mental illness that may lead to an increase in depressive moments and high emotional state. Psychotherapy and treatments such as antipsychotics and mood stabilizers are included in the medication of bipolar disorder. Growth in the bipolar disorder therapeutic industry is expected to speed up significantly over the next few years, driven by the increased prevalence of mental health disorders (MHDs) worldwide.

Most MHDs co-exist with other diseases like diabetes, cardiovascular disease and obesity, according to the CDC. Depression affected nearly 10%-12% of the younger population in the U.S. in 2017, and 3%-4% of the population ended up living with serious mental illnesses such as bipolar disorder, schizophrenia and major depression. The growing incidence of these MHDs leads to a great need to develop the most appropriate bipolar disorder treatment.

Bipolar disorder affects more than 5 million people in the United States, according to Pfizer, Inc. Bipolar episodes are distinguished by a dramatic behavioral change and emotional state, ranging from exaggerated and happy to terribly sad and depressive state. These abnormalities have various types of episodes, such as hypomanic episodes, manic episodes, mixed episodes and episodes of depression. Bipolar disorder triggers include stressful events in life, childhood trauma, genetic inheritance and problems with self-esteem.

Throughout the world, people represented “March 30” as a World Bipolar Day to create awareness of the disorder and eliminate the mental disorder stigma. Huge number of people with this mental condition depend on alcohol to lift their emotional state. Around 27% of people with bipolar disorder become dependent on alcohol, while over 15% are engaged in abuse of alcohol, as per the National Institute on Alcohol Abuse and Alcoholism.

Rising bipolar disorder prevalence, technological advancement, high unmet medical needs, and government initiatives are major factors that accelerate the growth of the bipolar disorder therapeutic market. The Salk Institute for Biological Studies and Johns Hopkins University School of Medicine co-led a $15.4 million commitment in 2016, as per the National Institute of Mental Health, to design new systems to quickly monitor drug databases for potential efficiency against bipolar disorder and schizophrenia. The other factors probable to fuel the bipolar disorder therapeutic market are excessive investment in research and development and cooperative activities between corporations for product innovation. Corium and Aequus started partnership on product design in 2015 focusing on CNS illnesses such as schizophrenia, bipolar disorder, autistic disorder, and other major depressive diseases. Stringent regulations, however, act as a major constraint on the bipolar disorder therapeutic market.

With the emergence of several vendors offering products for bipolar disorder treatment, the global bipolar disorder therapy market is expected to experience strong competition and diminishing profitability. Most sellers focus on entering into strategic partnerships to develop the most efficient bipolar treatment therapy and expand their portfolio of products. Many international and national vendors remain competitive for their share of the global bipolar disorder therapeutic market, and players need to distinguish to gain essential traction over their counterparts.

The key global players of bipolar disorder therapeutics market are Pfizer Inc., Glaxo SmithKline (GSK), Eli Lilly, Janssen Pharmaceuticals, Novartis AG, Allergan Plc., Otsuka Holdings Co. Ltd, AbbVie Inc., Bristol-Myers Squibb Company and AstraZeneca.

Table of Content

Chapter 1. Executive Summary

Chapter 2. Market Introduction

Chapter 3. Global Bipolar Disorder Therapeutics Market – Analysis and Revenue Forecast 2018-2025 – Key Industry Dynamics

  • 3.1. Key Market Drivers
  • 3.2. Key Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Future Trends
  • 3.5. Impact Analysis of Drivers and Restraints

Chapter 4. Global Bipolar Disorder Therapeutics Market – Analysis and Revenue Forecast 2018-2025

Chapter 5. Global Bipolar Disorder Therapeutics Market – Analysis and Revenue Forecast 2018-2025 – By Drug Class

  • 5.1. Mood Stabilizers
  • 5.2. Anticonvulsants
  • 5.3. Antipsychotic Drugs
  • 5.4. Antidepressant Drugs
  • 5.5. Antianxiety Drugs

Chapter 6. Global Bipolar Disorder Therapeutics Market – Analysis and Revenue Forecast 2018-2025 – Mechanism of Action

  • 6.1. Selective Serotonin Reuptake Inhibitor
  • 6.2. Serotonin Norepinephrine Reuptake Inhibitors
  • 6.3. Tricyclic Antidepressants
  • 6.4. Monoamine Oxidase Inhibitors
  • 6.5. Benzodiazepines
  • 6.6. Beta Blockers

Chapter 7. Global Bipolar Disorder Therapeutics Market – Analysis and Revenue Forecast 2018-2025 – By Region

  • 7.1. North America
  • 7.2. Europe
  • 7.3. Asia-Pacific
  • 7.4. Latin America
  • 7.5. Middle East & Africa

Chapter 8. North America Bipolar Disorder Therapeutics Market – Analysis and Revenue Forecast 2018-2025

  • 8.1. North America Bipolar Disorder Therapeutics Market – By Drug Class
    • 8.1.1.Mood Stabilizers
    • 8.1.2.Anticonvulsants
    • 8.1.3.Antipsychotic Drugs
    • 8.1.4.Antidepressant Drugs
    • 8.1.5.Antianxiety Drugs
  • 8.2. North America Bipolar Disorder Therapeutics Market – By Mechanism of Action
    • 8.2.1.Selective Serotonin Reuptake Inhibitor
    • 8.2.2.Serotonin Norepinephrine Reuptake Inhibitors
    • 8.2.3.Tricyclic Antidepressants
    • 8.2.4.Monoamine Oxidase Inhibitors
    • 8.2.5.Benzodiazepines
    • 8.2.6.Beta Blockers
  • 8.3. North America Bipolar Disorder Therapeutics Market – By Country
    • 8.3.1.U.S.
    • 8.3.2.Canada

Chapter 9. Europe Bipolar Disorder Therapeutics Market – Analysis and Revenue Forecast 2018-2025

  • 9.1. Europe Bipolar Disorder Therapeutics Market – By Drug Class
    • 9.1.1.Mood Stabilizers
    • 9.1.2.Anticonvulsants
    • 9.1.3.Antipsychotic Drugs
    • 9.1.4.Antidepressant Drugs
    • 9.1.5.Antianxiety Drugs
  • 9.2. Europe Bipolar Disorder Therapeutics Market – By Mechanism of Action
    • 9.2.1.Selective Serotonin Reuptake Inhibitor
    • 9.2.2.Serotonin Norepinephrine Reuptake Inhibitors
    • 9.2.3.Tricyclic Antidepressants
    • 9.2.4.Monoamine Oxidase Inhibitors
    • 9.2.5.Benzodiazepines
    • 9.2.6.Beta Blockers
  • 9.3. Europe Bipolar Disorder Therapeutics Market – By Country
    • 9.3.1.Germany
    • 9.3.2.France
    • 9.3.3.UK
    • 9.3.4.Spain
    • 9.3.5.Italy
    • 9.3.6.Rest of Europe

Chapter 10. Asia-Pacific Bipolar Disorder Therapeutics Market – Analysis and Revenue Forecast 2018-2025

  • 10.1. Asia Pacific Bipolar Disorder Therapeutics Market – By Drug Class
    • 10.1.1.Mood Stabilizers
    • 10.1.2.Anticonvulsants
    • 10.1.3.Antipsychotic Drugs
    • 10.1.4.Antidepressant Drugs
    • 10.1.5.Antianxiety Drugs
  • 10.2. Asia Pacific Bipolar Disorder Therapeutics Market – By Mechanism of Action
    • 10.2.1.Selective Serotonin Reuptake Inhibitor
    • 10.2.2.Serotonin Norepinephrine Reuptake Inhibitors
    • 10.2.3.Tricyclic Antidepressants
    • 10.2.4.Monoamine Oxidase Inhibitors
    • 10.2.5.Benzodiazepines
    • 10.2.6.Beta Blockers
  • 10.3. Asia-Pacific Bipolar Disorder Therapeutics Market – By Country
    • 10.3.1.China
    • 10.3.2.India
    • 10.3.3.Japan
    • 10.3.4.South Korea
    • 10.3.5.Rest of Asia-Pacific

Chapter 11. Latin America Bipolar Disorder Therapeutics Market – Analysis and Revenue Forecast 2018-2025

  • 11.1. Latin America Bipolar Disorder Therapeutics Market – By Drug Class
    • 11.1.1.Mood Stabilizers
    • 11.1.2.Anticonvulsants
    • 11.1.3.Antipsychotic Drugs
    • 11.1.4.Antidepressant Drugs
    • 11.1.5.Antianxiety Drugs
  • 11.2. Latin America Bipolar Disorder Therapeutics Market – By Mechanism of Action
    • 11.2.1.Selective Serotonin Reuptake Inhibitor
    • 11.2.2.Serotonin Norepinephrine Reuptake Inhibitors
    • 11.2.3.Tricyclic Antidepressants
    • 11.2.4.Monoamine Oxidase Inhibitors
    • 11.2.5.Benzodiazepines
    • 11.2.6.Beta Blockers
  • 11.3. Latin America Bipolar Disorder Therapeutics Market – By Country
    • 11.3.1.Brazil
    • 11.3.2.Mexico
    • 11.3.3.Rest of Latin America

Chapter 12. Middle East & Africa Bipolar Disorder Therapeutics Market – Analysis and Revenue Forecast 2018-2025

  • 12.1. Middle East & Africa Bipolar Disorder Therapeutics Market – By Drug Class
    • 12.1.1.Mood Stabilizers
    • 12.1.2.Anticonvulsants
    • 12.1.3.Antipsychotic Drugs
    • 12.1.4.Antidepressant Drugs
    • 12.1.5.Antianxiety Drugs
  • 12.2. Middle East & Africa Bipolar Disorder Therapeutics Market – By Mechanism of Action
    • 12.2.1.Selective Serotonin Reuptake Inhibitor
    • 12.2.2.Serotonin Norepinephrine Reuptake Inhibitors
    • 12.2.3.Tricyclic Antidepressants
    • 12.2.4.Monoamine Oxidase Inhibitors
    • 12.2.5.Benzodiazepines
    • 12.2.6.Beta Blockers
  • 12.3. Middle East & Africa Bipolar Disorder Therapeutics Market – By Country
    • 12.3.1.UAE
    • 12.3.2.Saudi Arabia
    • 12.3.3.Turkey
    • 12.3.4.Rest of Middle East & Africa

Chapter 13. Competitive Analysis

  • 13.1.1.Competition Dashboard
  • 13.1.2.Company Profiles
    • 13.1.2.1. Pfizer Inc.
    • 13.1.2.2. Glaxo SmithKline
    • 13.1.2.3. Novartis AG
    • 13.1.2.4. Eli Lilly
    • 13.1.2.5. Janssen Pharmaceuticals
    • 13.1.2.6. Allergan Plc.
    • 13.1.2.7. Otsuka Holdings Co. Ltd
    • 13.1.2.8. AbbVie Inc.
    • 13.1.2.9. Bristol-Myers Squibb Company
    • 13.1.2.10. AstraZeneca
Report Methodology
Report Customization
Report Sample
Consult the Analyst